Compass Pathways Stock News

GAINERS: Cybin (AMEX: CYBN ) shares closed up 4.25% at $0.94 Small Pharma (OTC: DMTTF ) shares closed up 1.43% at $0.23 Compass Pathways (NASDAQ: CMPS ) shares closed up 1.25% at $14.62 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 1.05% at $5.80 LOSERS: TripAdvisor (NASDAQ: TRIP ) shares … Full story available on Benzinga.com

CMPS earnings call for the period ending December 31, 2021.

GAINERS: Seelos Therapeutics (NASDAQ: SEEL ) shares closed up 11.06% at $1.10 Mind Medicine (NASDAQ: MNMD ) shares closed up 11.01% at $1.21 Compass Pathways (NASDAQ: CMPS ) shares closed up 4.50% at $13.23 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 3.83% at $5.42 Mindset Pharma (OTC: Full story available on Benzinga.com

COMPASS Pathways plc (NASDAQ: CMPS ) reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business. Q4 Financial Highlights Net loss totaled $25.7 million , or $0.61 loss per share, compared with $18.8 million, or $0.52 loss per share, during the same period in 2020. Research and development expenses were $13.6, compared with $4.5 million during the same period in 2020. General and administrative expenses were $14.7 million, compared with $7.0 million during the same period in 2020. 2021 Financial Highlights Net loss totaled 71.7 million, or $1.79 loss per share, compared with $60.3 million or $3.55 loss per share, … Full story available on Benzinga.com

COMPASS Pathways plc (CMPS) CEO George Goldsmith on Q4 2021 Results - Earnings Call Transcript

Related Stocks: SVFA , CCVI , CMPS , ROSS , PNM , FR , BCSAU , MEIP , BABA , HOOD , MOS , BTCM , HOV , GNLN , CFFE , AJRD , INKA , GOLD , RTPY , VHAQ , MBAC , CLAS , XOG , BSN ,

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022.

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in men

A new review study by Johns Hopkins University researchers is shedding light on the long-term effects of psilocybin in the treatment of major depression. In a new study, 58% of participants with major depressive disorder were in remission after one year of doing two sessions with psilocybin. “Psilocybin not only produces significant and immediate effects, it also has a long duration, which suggests that it may be a uniquely useful new treatment for depression,” said Roland Griffiths , Ph.D., Professor in Neuropsychopharmacology of Consciousness at Johns Hopkins School of Medicine. Psilocybin, also known as the active compound in “magic mushrooms,” is one of the compounds spearheading a pipeline that looks to advance psychedelic drugs for medical use. There are currently dozens of biotech companies developing psychedelic drugs for mental health indications. Compass Pathways (NASDAQ: CMPS ) is leading commercial research with … Full story available on Benzinga.com

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.

LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno

Compass Pathways Plc - ADR (CMPS) shares closed today at 1.8% above its 52 week low of $19.59, giving the company a market cap of $832M. The stock is currently down 9.8% year-to-date, down 54.9% over the past 12 months, and down 31.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 56.0% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1464.5% The company's stock price performance over the past 12 months lags the peer average by 613.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.